Cardiomyopathy is the leading cause of mortality in patients with DMD. Compared with their healthy counterparts, patients with DMD — including those with preserved left ventricular ejection fraction ...

Delandistrogene moxeparvovec showed significant long-term stabilization or slowed progression in DMD patients over 3 and 5 years compared to external controls. Clinical trials demonstrated ...

Capricor Therapeutics has presented positive long-term data from its HOPE-2 clinical trial at the 2025 Muscular Dystrophy Association Conference, indicating that its leading treatment, deramiocel, can ...

A new surprise discovery could hold big implications for muscular dystrophy patients, with researchers finding that an existing cancer drug may delay progression of the hard-to-treat disease.

Managing the transition to mobility aids is a pivotal part of life with DMD. Discover expert strategies for maintaining independence through physical therapy, adaptive technology, and home ...

Duchenne muscular dystrophy (DMD) is a genetic disease that causes muscle weakness and motor skill difficulties due to the loss of muscle tissue from changes to dystrophin proteins. It mostly affects ...

Researchers at UBC’s School of Biomedical Engineering have discovered that an existing cancer drug could have potential as a treatment for muscular dystrophy. Duchenne muscular dystrophy (DMD) is a ...

Duchenne muscular dystrophy (DMD) is a genetic disease that causes progressive muscle weakness. DMD commonly affects boys, where symptoms are seen in early childhood. There is currently no cure for ...

Delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), showed high dystrophin expression and a favorable safety profile in young patients. Delandistrogene moxeparvovec ...

There are many kinds of muscular dystrophies, which are caused by genetic mutations. These diseases reduce mobility, and complicate everyday tasks. Various types of muscular dystrophies can affect ...

The National Institute for Health and Care Excellence (NICE) has recommended givinostat for NHS use as an option to treat Duchenne muscular dystrophy (DMD). In its final draft guidance, the regulator ...

Your muscles need continuous maintenance to stay strong and healthy. Duchenne muscular dystrophy (DMD) happens when there is a change in a person's genetic instructions that affects the production of ...